Invention Grant
US09243051B2 Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T-cells
有权
用于治疗抗原特异性T细胞的单体重组MHC分子
- Patent Title: Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T-cells
- Patent Title (中): 用于治疗抗原特异性T细胞的单体重组MHC分子
-
Application No.: US13731711Application Date: 2012-12-31
-
Publication No.: US09243051B2Publication Date: 2016-01-26
- Inventor: Gregory G. Burrows , Arthur A. Vandenbark
- Applicant: Gregory G. Burrows , Arthur A. Vandenbark
- Applicant Address: US OR Portland US DC Washington
- Assignee: Oregon Health & Science University,The United States Government as Represented by the Department of Veterans Affairs
- Current Assignee: Oregon Health & Science University,The United States Government as Represented by the Department of Veterans Affairs
- Current Assignee Address: US OR Portland US DC Washington
- Agency: Klarquist Sparkman, LLP
- Main IPC: C12N15/62
- IPC: C12N15/62 ; C12N15/86 ; A61K39/00 ; C07K14/705 ; C07K14/74
Abstract:
The present invention provides, in particular embodiments, for modified recombinant T cell receptor (TCR) ligands (RTLs) comprising a MHC class I or MHC class II component. The modified RTLs have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind Ag-peptides, target antigen-specific T cells, inhibit T cell proliferation in an Ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific T cells in vivo.
Public/Granted literature
- US20130190221A1 MONOMERIC RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS Public/Granted day:2013-07-25
Information query
IPC分类:
